HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Advanced Breast Cancer|Advanced Breast Cancer|BRCA2 Mutation|BRCA1 Mutation
Interventions: DRUG: Palbociclib|DRUG: Olaparib|DRUG: Fulvestrant
Sponsor: Abramson Cancer Center at Penn Medicine